Pacific Biosciences of California, Inc. (PACB) Return on equity 2016–2025
Pacific Biosciences of California, Inc. (PACB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-10215.0%FY2025 · since FY2016: -87.8% → -10215.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -10215.0% | -10153.8 pp |
| FY2024 | -61.2% | -17.4 pp |
| FY2023 | -43.7% | +12.1 pp |
| FY2022 | -55.8% | -32.9 pp |
| FY2021 | -22.9% | -31.7 pp |
| FY2020 | 8.8% | +162.0 pp |
| FY2019 | -153.2% | -63.3 pp |
| FY2018 | -89.9% | +17.1 pp |
| FY2017 | -107.1% | -19.2 pp |
| FY2016 | -87.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice